Pulse Biosciences (NASDAQ: PLSE) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.
This is a summary of current recommendations for Pulse Biosciences and Intuitive Surgical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intuitive Surgical has a consensus price target of $406.13, indicating a potential downside of 3.70%. Given Intuitive Surgical’s higher possible upside, analysts plainly believe Intuitive Surgical is more favorable than Pulse Biosciences.
Insider and Institutional Ownership
11.6% of Pulse Biosciences shares are held by institutional investors. Comparatively, 61.6% of Intuitive Surgical shares are held by institutional investors. 6.7% of Pulse Biosciences shares are held by company insiders. Comparatively, 2.2% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Pulse Biosciences and Intuitive Surgical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Pulse Biosciences has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
Earnings and Valuation
This table compares Pulse Biosciences and Intuitive Surgical’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pulse Biosciences||N/A||N/A||-$9.51 million||($1.39)||-13.46|
|Intuitive Surgical||$3.13 billion||15.14||$660.00 million||$5.68||74.25|
Intuitive Surgical has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.
Intuitive Surgical beats Pulse Biosciences on 11 of the 12 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
About Intuitive Surgical
Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company’s da Vinci Surgical System consists of a surgeon’s console, a patient-side cart and a vision system. The da Vinci Surgical System translates a surgeon’s hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition (HD) vision. Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company’s instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.